Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its target price boosted by Guggenheim from $78.00 to $82.00 in a report published on Tuesday, The Fly reports. A number of other equities analysts have also recently weighed in on the stock. JMP Securities reaffirmed a market outperform rating and set a $114.00 price target on shares […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Investment analysts at Wedbush raised their Q2 2023 earnings per share estimates for Blueprint Medicines in a report issued on Tuesday, May 23rd. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will post earnings of ($2.45) per share for the quarter, up from their prior […]
StockNews.com initiated coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) in a report issued on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Several other equities research analysts have also commented on BPMC. VNET Group reiterated a maintains rating on shares of Blueprint Medicines in a research report on […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 3,800,000 shares, a decline of 11.8% from the April 15th total of 4,310,000 shares. Based on an average daily trading volume, of 596,800 shares, the short-interest ratio […]
EFG Asset Management Americas Corp. trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) by 5.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,927 shares of the biotechnology company’s stock after selling 357 shares during the period. EFG Asset Management Americas Corp.’s holdings in Blueprint Medicines were worth […]